|
1
|
Simonetti RG, Camma C, Fiorello F, Politi
F, D’Amico G and Pagliaro L: Hepatocellular carcinoma. a worldwide
problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carr BI: Hepatocellular carcinoma: current
management and future trends. Gastroenterology. 127(5 Suppl 1):
S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao B, Ye X, Yu J, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao B, Wei X, Li W, et al: Inactivation
of YAP oncoprotein by the hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zender L, Spector MS, Xue W, et al:
Identification and validation of oncogenes in liver cancer using an
integrative oncogenomic approach. Cell. 125:1253–1267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu MZ, Yao TJ, Lee NP, et al:
Yes-associated protein is an independent prognostic marker in
hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang C, Zhang L, He Q, et al: Differences
in yes-associated protein and mrna levels in regenerating liver and
hepatocellular carcinoma. Mol Med Rep. 5:410–414. 2012.
|
|
8
|
Hao Y, Chun A, Cheung K, Rashidi B and
Yang X: Tumor suppressor LATS1 is a negative regulator of oncogene
yap. J Biol Chem. 283:5496–5509. 2008. View Article : Google Scholar
|
|
9
|
Li H, Wolfe A, Septer S, et al:
Deregulation of hippo kinase signalling in human hepatic
malignancies. Liver Int. 32:38–47. 2012. View Article : Google Scholar
|
|
10
|
St John MA, Tao W, Fei X, et al: Mice
deficient of lats1 develop soft-tissue sarcomas, ovarian tumours
and pituitary dysfunction. Nat Genet. 21:182–186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Tang ZY, Ye SL, et al: Establishment
of cell clones with different metastatic potential from the
metastatic hepatocellular carcinoma cell line MHCC97. World J
Gastroenterol. 7:630–636. 2001.
|
|
12
|
Tian J, Tang ZY, Ye SL, et al: New human
hepatocellular carcinoma (HCC) cell line with highly metastatic
potential (MHCC97) and its expressions of the factors associated
with metastasis. Br J Cancer. 81:814–821. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramachandran V, Arumugam T, Wang H and
Logsdon CD: Anterior gradient 2 is expressed and secreted during
the development of pancreatic cancer and promotes cancer cell
survival. Cancer Res. 68:7811–7818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Liu XS, Jiang J, Jiao XY, Wu YE, Lin JH
and Cai YM: Lycorine induces apoptosis and down-regulation of Mcl-1
in human leukemia cells. Cancer Lett. 274:16–24. 2009. View Article : Google Scholar
|
|
16
|
Zhang J, Smolen GA and Haber DA: Negative
regulation of YAP by LATS1 underscores evolutionary conservation of
the drosophila hippo pathway. Cancer Res. 68:2789–2794. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu MZ, Chan SW, Liu AM, et al: AXL
receptor kinase is a mediator of YAP-dependent oncogenic functions
in hepatocellular carcinoma. Oncogene. 30:1229–1240. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Camargo FD, Gokhale S, Johnnidis JB, et
al: YAP1 increases organ size and expands undifferentiated
progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, George J, Deb S, et al: The Hippo
pathway transcriptional co-activator, YAP, is an ovarian cancer
oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JM, Kang DW, Long LZ, et al:
Differential expression of yes-associated protein is correlated
with expression of cell cycle markers and pathologic TNM staging in
non-small-cell lung carcinoma. Hum Pathol. 42:315–323. 2011.
View Article : Google Scholar
|
|
21
|
Visser S and Yang X: LATS tumor
suppressor: a new governor of cellular homeostasis. Cell cycle.
9:3892–3903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chow A, Hao Y and Yang X: Molecular
characterization of human homologs of yeast MOB1. Int J Cancer.
126:2079–2089. 2010.
|
|
23
|
Xiao L, Chen Y, Ji M and Dong J: KIBRA
regulates hippo signaling activity via interactions with large
tumor suppressor kinases. J Biol Chem. 286:7788–7796. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho KC, Zhou Z, She YM, Chun A, Cyr TD and
Yang X: Itch E3 ubiquitin ligase regulates large tumor suppressor 1
stability [corrected]. Proc Natl Acad Sci USA. 108:4870–4875. 2011.
View Article : Google Scholar
|
|
25
|
Yeung B, Ho KC and Yang X: WWP1 E3 ligase
targets LATS1 for ubiquitin-mediated degradation in breast cancer
cells. PLoS One. 8:e610272013. View Article : Google Scholar : PubMed/NCBI
|
